Kiniksa (KNSA) shifts from survival to growth as Arcalyst nears blockbuster sales and pipeline KPL-387 readouts loom—get the ...
The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple ...
Nirsevimab may offer infants stronger protection against severe respiratory syncytial virus than maternal vaccination, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results